OBJECTIVE: To examine trends in resource use and the effect of incident diabetic macular edema (DME) on 1- and 3-year total direct medical costs in elderly patients. METHODS: We used a nationally representative 5% sample of Medicare beneficiaries from 2000 through 2004 to identify patients with incident DME and a control cohort of patients with diabetes mellitus but no history of retinal disease. We summed Medicare reimbursement amounts for all claims and applied generalized linear models to estimate the effect of DME on 1- and 3-year costs. We also examined the use of select imaging techniques and treatments. RESULTS: After adjusting for demographic characteristics and baseline comorbid conditions, DME was associated with 31% higher 1-year costs and 29% higher 3-year costs. There were significant shifts in the use of testing and treatment modalities. From 2000 to 2004, use of intravitreal injection increased from 1% to 13% of patients; use of optical coherence tomography increased from 2.5% to more than 40%. Use of laser photocoagulation decreased over time. CONCLUSIONS: After adjusting for demographic variables and baseline comorbid conditions, new-onset DME was a significant independent predictor of total medical costs after 1 and 3 years. Diagnostic and treatment modalities used for DME have changed significantly.
OBJECTIVE: To examine trends in resource use and the effect of incident diabetic macular edema (DME) on 1- and 3-year total direct medical costs in elderly patients. METHODS: We used a nationally representative 5% sample of Medicare beneficiaries from 2000 through 2004 to identify patients with incident DME and a control cohort of patients with diabetes mellitus but no history of retinal disease. We summed Medicare reimbursement amounts for all claims and applied generalized linear models to estimate the effect of DME on 1- and 3-year costs. We also examined the use of select imaging techniques and treatments. RESULTS: After adjusting for demographic characteristics and baseline comorbid conditions, DME was associated with 31% higher 1-year costs and 29% higher 3-year costs. There were significant shifts in the use of testing and treatment modalities. From 2000 to 2004, use of intravitreal injection increased from 1% to 13% of patients; use of optical coherence tomography increased from 2.5% to more than 40%. Use of laser photocoagulation decreased over time. CONCLUSIONS: After adjusting for demographic variables and baseline comorbid conditions, new-onset DME was a significant independent predictor of total medical costs after 1 and 3 years. Diagnostic and treatment modalities used for DME have changed significantly.
Authors: Elena Birman-Deych; Amy D Waterman; Yan Yan; David S Nilasena; Martha J Radford; Brian F Gage Journal: Med Care Date: 2005-05 Impact factor: 2.983
Authors: C A Puliafito; M R Hee; C P Lin; E Reichel; J S Schuman; J S Duker; J A Izatt; E A Swanson; J G Fujimoto Journal: Ophthalmology Date: 1995-02 Impact factor: 12.079
Authors: M R Hee; C A Puliafito; J S Duker; E Reichel; J G Coker; J R Wilkins; J S Schuman; E A Swanson; J G Fujimoto Journal: Ophthalmology Date: 1998-02 Impact factor: 12.079
Authors: Hude Quan; Vijaya Sundararajan; Patricia Halfon; Andrew Fong; Bernard Burnand; Jean-Christophe Luthi; L Duncan Saunders; Cynthia A Beck; Thomas E Feasby; William A Ghali Journal: Med Care Date: 2005-11 Impact factor: 2.983
Authors: M R Hee; C A Puliafito; C Wong; J S Duker; E Reichel; B Rutledge; J S Schuman; E A Swanson; J G Fujimoto Journal: Arch Ophthalmol Date: 1995-08
Authors: John A Wells; Adam R Glassman; Allison R Ayala; Lee M Jampol; Lloyd Paul Aiello; Andrew N Antoszyk; Bambi Arnold-Bush; Carl W Baker; Neil M Bressler; David J Browning; Michael J Elman; Frederick L Ferris; Scott M Friedman; Michele Melia; Dante J Pieramici; Jennifer K Sun; Roy W Beck Journal: N Engl J Med Date: 2015-02-18 Impact factor: 91.245
Authors: Suzann Pershing; Eva A Enns; Brian Matesic; Douglas K Owens; Jeremy D Goldhaber-Fiebert Journal: Ann Intern Med Date: 2014-01-07 Impact factor: 25.391
Authors: Eric W Schneider; Prithvi Mruthyunjaya; Nidhi Talwar; Kristen Harris Nwanyanwu; Bin Nan; Joshua D Stein Journal: Invest Ophthalmol Vis Sci Date: 2014-01-29 Impact factor: 4.799